| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MED24; SURF5; surf-5 |
| Entrez GeneID | 6837; |
| WB Predicted band size | 22kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于MED22抗体的3篇文献示例(内容为虚构，供格式参考)：
---
1. **文献名称**: "MED22 mediates transcriptional elongation through RNA polymerase II interaction"
**作者**: Smith A, et al.
**摘要**: 本研究利用MED22特异性抗体进行ChIP-seq分析，揭示了MED22在中介体复合物中促进RNA聚合酶II转录延伸的作用，尤其在基因启动子-近端区域富集。
2. **文献名称**: "Structural role of MED22 in the Mediator complex assembly"
**作者**: Chen L, et al.
**摘要**: 通过冷冻电镜技术和MED22抗体的免疫沉淀实验，阐明了MED22亚基在中介体复合物头模块中的结构定位，及其在稳定复合物构象中的关键功能。
3. **文献名称**: "MED22 deficiency links to inflammatory response dysregulation via cytokine genes"
**作者**: Kim S, et al.
**摘要**: 使用MED22敲除模型及抗体进行Western blot验证，发现MED22通过调控NF-κB靶基因的转录，影响巨噬细胞的炎症反应，提示其与自身免疫疾病的潜在关联。
---
注：以上文献为示例，实际引用时请以真实发表的论文为准。建议通过PubMed或Web of Science搜索关键词“MED22 antibody”获取最新研究。
The MED22 antibody targets the MED22 protein, a critical subunit of the Mediator complex—a multi-protein assembly essential for regulating RNA polymerase II (Pol II)-dependent transcription in eukaryotes. The Mediator complex acts as a molecular bridge, facilitating communication between transcription factors and the basal transcriptional machinery. MED22. also known as Mediator of RNA Polymerase II Transcription Subunit 22. plays a role in stabilizing the overall architecture of the Mediator and modulating its interactions with Pol II. Studies suggest that MED22 is involved in diverse cellular processes, including cell growth, differentiation, and stress responses. Dysregulation of MED22 has been linked to developmental disorders and cancers, highlighting its biological and clinical relevance.
Antibodies against MED22 are widely used in research to investigate its expression, localization, and molecular interactions. They enable techniques such as Western blotting, immunofluorescence, chromatin immunoprecipitation (ChIP), and co-immunoprecipitation (Co-IP) to explore MED22's role in gene regulation. Commercially available MED22 antibodies are typically raised in hosts like rabbits or mice, using recombinant protein fragments or synthetic peptides as immunogens. Validation often includes knockout/knockdown controls to confirm specificity. Researchers utilize these tools to dissect Mediator complex dynamics in diseases, screen for therapeutic targets, or study transcriptional mechanisms in model organisms. Proper validation remains crucial due to potential cross-reactivity with other Mediator subunits or unrelated proteins.
×
